Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Samsung Seeks Third Anti-TNF Biosimilar Launch In Europe

Executive Summary

After receiving regulatory approvals in Europe for its biosimilar versions of etanercept and infliximab earlier this year, South Korea's Samsung Bioepis is now looking to add adalimumab to it and partner Biogen’s growing portfolio.

You may also be interested in...

'Uncomfortable' Panel Backs Amgen Biosimilar, But Uphill Battle To Sway Docs, Public

A tense advisory committee meeting, where many of the panelists admitted they lacked a complete understanding about biosimilars and patient advocates expressed anxiety over the products, could signal difficulties with adoption and success in the marketplace.

Samsung Bioepis Taps Infliximab As Its US Biosimilar Pioneer

A month after the US FDA granted approval of Celltrion's biosimilar infliximab, another South Korean firm, Samsung Bioepis, is rapidly progressing its diverse pipeline and is seeking an entry into the US market through an approval filing for its biosimilar version of the anti-inflammatory antibody. The product is already available in South Korea and recently won a green light in Europe.

Samsung Bioepis's Etanercept Biosimilar To Be Rolled Out In Europe

Samsung Bioepis Co. Ltd. has received a marketing approval from the European Commission for its biosimilar version of Amgen Inc.'s Enbrel (etanercept), the first etanercept biosimilar to be approved by the Commission and therefore likely the first to debut in Europe. But Sandoz is close behind – the Swiss company's biosimilar etanercept was accepted by review by European regulators in December 2015.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts